Immunotherapy vs Targeted Therapy — They Are Not the Same

Targeted therapy is a precision drug that blocks one specific molecular fault driving your particular cancer — an EGFR mutation, an ALK rearrangement, a BRAF mutation, or HER2 amplification, for example — found through tumour molecular testing. Immunotherapy works in a completely different way: it does not target the cancer cell directly at all. Instead, it releases a brake on your own immune system so your body's defences can recognise and attack cancer cells, based on separate biomarkers such as PD-L1 expression or MSI-High/dMMR status.

This confusion comes up constantly, including in family conversations, because both are described as "modern" or "advanced" treatments in the news. In reality, one is a lock-and-key drug for a mutation; the other is immune-system support. See who is eligible for immunotherapy — and who is not for the fuller eligibility picture on the immunotherapy side of this comparison.

Most patients in India are not automatically eligible for either treatment. Eligibility for targeted therapy depends on finding an actionable driver mutation in your tumour; eligibility for immunotherapy depends on a separate biomarker result. Neither is decided by preference or by which name sounds more advanced.

Usually not, and this surprises many families expecting "more treatment" to mean "better odds." For cancers driven by a targetable mutation — certain EGFR-mutant or ALK-positive lung cancers, for example — targeted therapy alone is typically the guideline-preferred first step under NCCN and ASCO recommendations, not a combination with immunotherapy.

In several of these mutation-positive cancers, adding checkpoint inhibitor immunotherapy has not shown a clear added benefit over targeted therapy alone, and combining the two can raise the risk of side effects rather than improve the outcome. Combination approaches are being studied in clinical trials for select situations — see is immunotherapy only for Stage 4 cancer? for how trial-stage combinations differ from standard care.

Outside a clinical trial, your oncology team will usually recommend one pathway at a time, chosen from your specific mutation and biomarker results — not both by default.

1. 1

   Confirm the exact diagnosis and stage

   The cancer's type, subtype, and stage narrow which mutations and biomarkers are even worth testing for.

2. 2

   Molecular testing on your tumour tissue

   A pathology lab checks for actionable driver mutations (EGFR, ALK, ROS1, BRAF, HER2, and others) and, separately, immunotherapy biomarkers such as PD-L1 or MSI-High/dMMR.

3. 3

   A matching mutation usually wins first

   Where an approved targeted therapy exists for your exact mutation, it typically becomes the guideline-preferred first step, ahead of immunotherapy.

4. 4

   Tumour board review

   Multiple oncologists — medical, surgical, and radiation — review your complete report together, rather than one doctor deciding alone.

5. 5

   The plan — and the honest alternative

   Sometimes the answer is targeted therapy, sometimes immunotherapy, sometimes neither matches and chemotherapy remains the backbone. For a smaller group of patients, best supportive care alone is discussed as a genuine option too.

Targeted therapy is often an oral tablet you take at home, once or twice a day, on an ongoing basis for as long as it keeps working and is tolerated — a very different rhythm from a hospital visit. Immunotherapy, by contrast, is given as an intravenous infusion at a day-care centre, typically every two to six weeks depending on the specific regimen, and requires supervised visits each time.

This practical difference — daily tablets versus periodic infusion visits — is itself a real factor in your family's planning, alongside the medical decision of which pathway even applies to your case. Both are managed under close monitoring; neither is a "set and forget" medication.

Most cancer patients do not have an actionable driver mutation or an immunotherapy-qualifying biomarker — this is common, not unusual, and it does not mean fewer real options. Chemotherapy, often alongside surgery or radiation, remains the guideline-preferred backbone treatment for many cancers. For some patients — particularly those who are frail or have widespread disease where any active treatment would carry more burden than benefit — best supportive (palliative) care alone is a genuine, guideline-recognised path too, not a failure to treat.

See what happens if you do nothing — comparing treatment with best supportive care for a fuller, honest look at that option where it is genuinely on the table.

CION's tumour board reviews your cancer type, stage, and full molecular and biomarker testing together before recommending targeted therapy, immunotherapy, chemotherapy, or a combination path where one genuinely applies — decisions for healing, not billing. If your team has already started planning your treatment plan, see understanding your treatment plan: cycles, weeks and duration, and if surgery is also part of your picture, see immunotherapy before surgery: what neoadjuvant treatment does. For the fuller picture of how immunotherapy is used and monitored at CION, see Immunotherapy at CION Cancer Clinics.

This page compares immunotherapy and targeted therapy in general terms to support your conversation with an oncologist — it does not recommend one treatment over another for your specific case. Mutation, biomarker, and side-effect descriptions here are general, guideline-sourced information (NCCN, ASCO), not predictions for any individual. Only your treating oncology team, reviewing your complete molecular-testing report, can advise on eligibility and treatment choice.

Thousands have weighed this same choice with our team

Comparing two treatment paths from search results is not the same as reviewing your actual molecular report with an oncologist. Take the first step today — our team walks this part of the journey with you.